Valuation: Patrys Limited

Market Cap 1.28Cr 88.08L 79L 72.2L 65.91L 1.24Cr 83Cr 8.7Cr 3.47Cr 44Cr 3.31Cr 3.24Cr 139.47Cr P/E 2025
-0.68x
P/E 2026 -4.22x
Enterprise Value 94.49L 64.98L 58.28L 53.26L 48.62L 91.6L 61Cr 6.42Cr 2.56Cr 33Cr 2.44Cr 2.39Cr 102.89Cr EV / Sales 2025
1.96x
EV / Sales 2026 2,223x
Free-Float
70.71%
Yield 2025 *
-
Yield 2026 -
1 day-4.35%
1 week-8.33%
Current month-8.33%
1 month-29.03%
3 months-33.33%
6 months-29.03%
Current year-21.43%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.02
0.03
Current year 0.02
Extreme 0.02
0.05
1 year 0.02
Extreme 0.02
0.05
3 years 0.01
Extreme 0.011987
0.13
5 years 0.01
Extreme 0.011987
0.54
10 years 0.01
Extreme 0.011987
0.91
Manager TitleAgeSince
Chief Executive Officer - 16/02/2026
Corporate Secretary - 10/11/2025
Corporate Secretary - 10/11/2025
Director TitleAgeSince
Director/Board Member - 17/06/2025
Chairman 64 -
Director/Board Member - 10/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
11/08/23 Expiration

Chief Executive Officer

3,96,132 0.0193%
11/08/23 Expiration

Chief Executive Officer

3,283 0.0002%
06/12/21 Buy

Chief Executive Officer

13,37,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
-4.35%-8.33%-45.00%-79.63% 88.08L
-4.83%+3.51%+53.62%+61.75% 6.59TCr
-1.34%+2.98%+24.79%+100.18% 5.65TCr
+0.02%+1.07%+10.63%+76.66% 5.69TCr
+5.09%+9.89%+22.45%+107.48% 4.65TCr
+2.62%+1.68%+28.91%+37.01% 4.48TCr
+8.24%+0.51%+213.26%+792.66% 4.16TCr
-1.86%+10.13%+26.82%+53.22% 3.53TCr
-2.97%-9.84%+88.86%+76.17% 3.33TCr
-2.18%+7.06%+36.06%-4.95% 2.49TCr
Average -0.16%+1.73%+46.04%+122.06% 4.06TCr
Weighted average by Cap. +0.21%+3.40%+53.12%+142.95%

Financials

2025 2026
Net sales 8L 6L 5L 5L 4L 8L 5.36Cr 56.29L 22.45L 2.86Cr 21.39L 20.93L 9.02Cr 8.98T 6.18T 5.54T 5.06T 4.62T 8.71T 6L 61.05T 24.34T 3L 23.19T 22.69T 10L
Net income -30.13L -20.72L -18.59L -16.99L -15.5L -29.21L -19Cr -2.05Cr -81.64L -10Cr -77.78L -76.11L -33Cr -34.15L -23.49L -21.07L -19.25L -17.57L -33.11L -22Cr -2.32Cr -92.53L -12Cr -88.16L -86.27L -37Cr
Net Debt -7L -5L -5L -4L -4L -7L -4.8Cr -50.44L -20.11L -2.56Cr -19.16L -18.75L -8.08Cr -33.6L -23.11L -20.72L -18.94L -17.29L -32.57L -22Cr -2.28Cr -91.03L -12Cr -86.73L -84.87L -37Cr
Projected Income Statement - Annual - Patrys Limited
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
05/26/05 A$0.0220 -4.35% 3,70,603
04/26/04 A$0.0230 -8.00% 64,169
03/26/03 A$0.0250 0.00% 400
02/26/02 A$0.0250 +4.17% 5,052
30/26/30 A$0.0240 -4.00% 1,707